April 08, 2026·daily

US Executive Compensation Proxy SEC Filings — April 08, 2026

Across 50 DEF 14A proxy statements filed around April 8, 2026, for May 2026 annual meetings, overarching themes include routine approvals for director elections (avg 8-12 nominees, 80%+ independent), advisory say-on-pay votes (with pay-vs-performance disclosures for 2021-2025 across most), and auditor ratifications, amid strong 2025 financials in energy (e.g., Venture Global +177% YoY revenue) and REITs (Kimco 96.4% occupancy), contrasted by consumer softness (Kenvue -2.1% sales YoY). Portfolio-level trends show 12/50 companies reporting revenue growth >10% YoY (avg +45% in energy), margin expansions in 8/50 (e.g., Kenvue op margin +410 bps), and robust capital allocation like dividends +4% YoY (Kimco) and buybacks (Rexford $250M). Positive sentiment dominates energy/REITs (9/10 high materiality), mixed/neutral in biotech/healthcare due to comp cuts (Precision Bio CEO -49%) despite goal attainments. Critical developments: Kenvue-Kimberly-Clark merger close H2 2026, ProPetro PROPWRSM scaling to 550 MW, and board refreshes signaling governance upgrades. Market implications favor energy/REIT overweight amid growth, caution on consumer/biotech volatility pre-meetings.

50 high priority50 total filings

April 08, 2026·daily

US Executive Officer Management Changes SEC — April 08, 2026

Across 23 SEC 8-K filings on USA executive and director changes from April 8, 2026, a high volume of leadership transitions is evident, with 12 new appointments/promotions (e.g., CFOs at FactSet, Universal Logistics, Forward Industries) and 8 departures/resignations (e.g., CFO at Scorpius, CEO at SoCalGas), signaling sector-wide refreshes amid strategic shifts. Finance and banking dominate (9/23 filings, including MVB, Popular, FinWise), showing proactive succession planning with positive sentiment in 40% of cases, while tech/AI firms like Mawson Infrastructure highlight activist-driven overhauls. No explicit YoY/QoQ financial deteriorations noted, but sudden events like Horizon Kinetics CEO death introduce mixed sentiment and transition risks; equity grants/RSUs in 5 filings (e.g., SpringBig's 12.9M CEO RSUs) indicate retention-focused capital allocation. Portfolio-level pattern: Smooth transitions with experienced hires (avg 20+ years exp in 7 cases) suggest stability, but interim roles (e.g., SoCalGas COO) flag near-term execution risks. Market implications include potential volatility around effective dates (cluster Apr-May 2026) and opportunities in undervalued firms post-turnover.

23 high priority23 total filings

April 08, 2026·daily

US Corporate Board Director Changes SEC Filings — April 08, 2026

Across 23 SEC 8-K filings on USA Board Room Changes dated April 8, 2026, there is elevated C-suite turnover, with 8 CFO transitions (resignations at Scorpius, Universal; appointments at FactSet, Spectral AI, Forward Industries, Catalyst Crew, Universal successor), 7 CEO-related shifts (new agreements at SpringBig/Parks America, death at Horizon Kinetics with co-CEOs, resignations at SoCalGas, new CEOs at Mawson/Navient/FinWise), and multiple director resignations (Byrna, OFA Group, Patriot National, USCB). Sentiment skews neutral (12/23) with positive tones on experienced hires and smooth successions (8 positive), mixed only at Horizon due to sudden loss of founder-CEO. No explicit YoY/QoQ financial trends or insider buys/sells reported, but equity-heavy comp packages (e.g., SpringBig CEO 12.9M RSUs, Spectral 150K options) and Change-in-Control protections signal retention amid M&A risks/opportunities. Financial sector dominates (9/23 filings: MVB, FactSet, Horizon, Universal, Patriot, Popular, Navient, FinWise, USCB) with planned transitions enhancing stability, while sudden events (Horizon death, SoCalGas CEO exit) raise interim leadership risks. Portfolio implication: Monitor finance/banking for execution continuity; leadership upgrades in tech/biotech (FactSet, Spectral, Mawson) offer relative outperformance potential vs. laggards with voids.

23 high priority23 total filings

April 07, 2026·daily

US Executive Compensation Proxy SEC Filings — April 07, 2026

Across 50 DEF 14A filings for US companies' 2026 annual meetings (primarily May 19-21), a dominant theme is robust 2025 fiscal performance with 14 companies explicitly reporting YoY revenue growth (avg +28%, range 4%-98%) in sectors like transport/logistics (XPO +LTL EBITDA 4% YoY), airlines (United +7.3% pre-tax margin), pharma (Collegium +48% Jornay PM), and fintech (Bread Financial net income +87% YoY), signaling broad economic resilience despite isolated challenges. Neutral sentiment prevails (32/50), with positive in 12 (e.g., Target Hospitality $0 net debt, Global Net Lease 32% TSR) and mixed in 2; no explicit guidance cuts but forward-looking catalysts include auditor ratifications for FY2026, equity plan expansions (e.g., Mistras +1.7M shares), and PDUFA dates (INOVIO Oct 2026). Capital allocation leans shareholder-friendly with buybacks (Collegium $25M, Rush $193.5M), dividends (Rush +5.6%), and debt reduction (Global Net Lease $2.2B), though dilution risks from incentive plan increases in 5 firms. Portfolio-level trend: 8/14 reporting firms show margin stability/improvement (e.g., XPO LTL +80bps), outperforming peers; sector patterns favor transport/pharma over REITs/funds. Market implication: Buy dips in high-performers pre-May meetings for potential say-on-pay catalysts and TSR boosts.

50 high priority50 total filings

April 07, 2026·daily

US Executive Officer Management Changes SEC — April 07, 2026

Across 36 filings on April 7, 2026, executive and director changes dominate with 24 appointments/promotions (e.g., new CEOs at ATN, Duos; CFOs at Velo3D, PSQ; board adds in biotech/pharma like Abeona, Stoke, TriSalus) outpacing 14 resignations/step-downs (e.g., CFO terminations at Protagenic, AB Intl; retirements at Levi, Mattel), signaling broad leadership refreshment and stability via planned transitions in 70% of cases. Financial enriched data sparse but highlights Kura Sushi Q2 FY2026 sales +23.3% YoY to $80M, comp sales +8.6% (4.3% traffic/price), Adj EBITDA +103.7% to $5.5M, restaurant margins +90bps to 18.2%, FY guidance $333-335M (16 new units); Capital One completed $2.56B Brex acquisition with special $2M RSU to exec. No portfolio-wide margin compression (only Kura food costs +170bps YoY due to tariffs); equity-heavy comp (RSUs/PSUs in Velo3D, ADTRAN, Kaival) aligns management, while salary hikes (Unusual Machines + to $350k CEO) imply minor cost pressures. Sector patterns: biotech/pharma (8/36) adding audit/med experts amid catalysts (Corbus ASCO May 2026); telecom/real estate (ATN, Ares) CEO/board shifts for growth. Net positive sentiment (18 positive/mixed-positive vs 3 negative), high materiality in CEO/CFO changes (avg 7.5/10); actionable: favor smooth transitions, watch sudden exits for volatility.

36 high priority36 total filings

April 07, 2026·daily

US Corporate Board Director Changes SEC Filings — April 07, 2026

Across 36 SEC filings on USA Board Room Changes dated April 7, 2026, a surge in C-suite and board transitions dominates, with 22 appointments/promotions (e.g., new CEOs, CFOs, directors) signaling proactive leadership refreshes, contrasted by 14 resignations/step-downs, often amicable and tied to personal reasons or planned successions. Positive sentiment prevails in 14 filings (e.g., expert hires in biotech/finance), neutral in 16, mixed/negative in 6, highlighting sector-specific board strengthening amid strategic pivots like Xponential Fitness' sale review. Limited period-over-period financials show outliers like Kura Sushi USA's Q2 FY2026 revenue up 23.3% YoY to $80M, comp sales +8.6%, but margin pressures from costs (food/bev +170 bps YoY); no broad insider trading patterns, but equity-heavy comp (RSUs, PSUs) in 12 firms indicates alignment. Forward-looking catalysts cluster in biotech (e.g., Corbus ASCO 2026 data, mid-2026 trials) and retail (Kura 16 new units FY2026). Capital allocation tilts to retention via bonuses/salary hikes (e.g., Unusual Machines +$350k CEO salary), with M&A integration (Capital One/Brex). Portfolio implication: Biotech/healthcare shows turnover as growth signal; monitor small-cap finance for stability risks.

36 high priority36 total filings

April 06, 2026·daily

US Executive Compensation Proxy SEC Filings — April 06, 2026

Across 50 DEF 14A proxy statements filed around April 6, 2026, a dominant theme is robust 2025 financial performance in 12 companies with disclosed metrics, averaging ~10% YoY revenue growth (e.g., JPM +record $185.6B, Howmet +11.1% sales, Quest +11.8%), strong ROE/ROTC (JPM 17%/20%, Horace Mann core ROE +300bps to 12.4%), and shareholder returns via buybacks/dividends (Assurant $468.3M returned, Middlesex 53 yrs dividend growth). Board refreshes and diversity are emphasized (Principal 50% women independents, MAA 7/9 independent), with 8 CEO/exec transitions noted as seamless (Core Molding, Alkermes). Mixed sentiments in REITs/apartments (MAA SS NOI -1.36% miss) contrast positive industrials/aerospace, but neutral governance dominates 70% filings. Capital allocation favors returns (Dorman $41M buybacks, Quest $450M repurchases) over aggressive M&A. Implications: Bullish for financials/insurers with payout growth, watch REITs for occupancy trends; portfolio-level margin stability (no widespread compression) supports overweight high-ROE names ahead of May 2026 meetings.

50 high priority50 total filings

April 06, 2026·daily

US Executive Officer Management Changes SEC — April 06, 2026

Across 31 filings on USA executive and director changes from April 6, 2026, the dominant theme is robust C-suite and board refreshment, with 18 new appointments/promotions (9 CFOs, 4 CEOs, 5+ directors) signaling strategic hiring for growth amid AI, energy demand, and profitability inflection points, versus 13 departures/retirements/terminations. Positive sentiment prevails in 35% of cases (11/31), particularly tech/health/energy sectors with hires boasting cap markets, ops, and scaling expertise (e.g., Oracle 20%+ organic revenue growth, Nerdy FY2026 rev guidance $180-190M, EBITDA breakeven). Neutral sentiment in 55% reflects orderly transitions without disagreements, but mixed signals like FuelCell director opposition (3.6M votes against) and sudden terminations (HealthEquity CTO) flag potential governance risks. No broad YoY revenue declines noted, but portfolio-level trend shows margin improvements in 4 cases (Nerdy +1000bps EBITDA margin implied), continuity in large caps (Cheniere seamless Chairman shift), and heightened retention incentives (Heron exec severance enhancements). Market implications include near-term catalysts from retirements (TVA CEO July 1) and M&A closes (Hologic go-private April 7), favoring longs in growth refreshes while monitoring small-cap churn (e.g., Treasure Global, Solo Brands OTC suspension). Overall, bullish for sectors with proven succession (energy/tech) vs. watch utilities/small caps.

31 high priority31 total filings

April 06, 2026·daily

US Corporate Board Director Changes SEC Filings — April 06, 2026

Across 31 SEC filings on USA Board Room Changes from April 6, 2026, there is elevated C-suite and board turnover with 18 appointments/promotions (e.g., 9 CFO roles) and 13 departures/retirements, skewed positive in tech, energy, and insurance sectors amid growth narratives. Key period trends include strong historical performance like Hologic's 65% revenue growth and 241% share price rise under retiring CEO, Oracle's >20% YoY organic revenue growth, and Nerdy's FY2026 guidance of $180-190M revenue with breakeven EBITDA (1,000bps margin expansion from 2025). Neutral sentiment dominates (19/31), but positive tones in 9 filings highlight expertise additions for scaling (e.g., AI-driven firms like DeFi Development Corp.). Critical implications: CFO influx signals financial discipline for expansion in energy (Expand Energy, Murphy USA) and tech (Oracle, Nerdy); CEO retirements at TVA (July 1) and Hologic (April 7 post-LBO) pose succession risks. Portfolio pattern: 7/12 energy/utility filings show leadership continuity for LNG/AI demand, contrasting sporadic director oppositions (e.g., FuelCell's 3.6M votes against). No broad margin compression but isolated incentives (Broadwind STIP payouts) amid capex reinvestment.

31 high priority31 total filings

April 03, 2026·daily

US Executive Compensation Proxy SEC Filings — April 03, 2026

Across 50 DEF 14A filings for 2026 proxy statements, a dominant theme is robust 2025 financial performance in industrials, REITs, and tech sectors, with 12 companies reporting revenue growth exceeding 10% YoY (e.g., GE Vernova +9%, CBRE +13.4%, ITT +8%) and strong capital returns via dividends and buybacks totaling billions (e.g., GE Vernova $3.6B returned, Royal Gold $1.2B since 2000). Margin expansions and FFO/NOI growth highlight operational resilience (e.g., LXP occupancy +350bps to 97.1%, Skyworks non-GAAP margin 24.4%), though food and select REITs show mixed results with GAAP declines amid volatility (e.g., NHI net income -3.5% YoY, Kraft Heinz GAAP EPS -$4.93). M&A activity surges as a catalyst (9 deals noted, including GE Vernova's $5.3B Prolec, ITT's $4.775B SPX FLOW), signaling consolidation and growth conviction. Capital allocation favors shareholders with dividend hikes (e.g., GE Vernova doubled to $2/share, Skyworks to $0.71) and buybacks, while forward-looking guidance points to sustained growth (e.g., Mondelez 3-5% organic revenue). Portfolio-level trends indicate outperformance vs. benchmarks (e.g., CBRE TSR beats S&P 500 across 1/3/5yr), but watch for say-on-pay votes and board refreshes at May-June 2026 meetings. Overall, bullish for industrials/REITs, neutral-mixed elsewhere, with alpha in M&A plays.

50 high priority50 total filings

April 03, 2026·daily

US Executive Officer Management Changes SEC — April 03, 2026

Across 38 SEC filings on US executive and director changes from April 3, 2026, the dominant theme is high turnover with over 25 resignations/departures (mostly directors and CFOs) stated as not due to disagreements, indicating routine board refreshes rather than operational distress; healthcare/biotech saw 9 events (e.g., COO death at HeartSciences, CFO appointments). Positive retention signals in 7 filings include $41.5M LTRP at MercadoLibre, $5M+ equity awards at ETHZilla, and $528k bonuses at Gibraltar, with no performance declines reported across multiple firms. Negative outliers include covenant breach threats and COO termination at Atlantic International (debt <$50M disputed as satisfied) and Intel's CLO exit. Period-over-period trends show stable metrics (no YoY/QoQ declines noted in 15+ filings), with forward-looking stability via reaffirmed guidance at WW International and 2026 bonus metrics at MercadoLibre. Portfolio implications: small-cap leadership stability supports hold; monitor finance/healthcare for transition risks amid neutral sentiment (26/38 neutral).

38 high priority38 total filings

April 03, 2026·daily

US Corporate Board Director Changes SEC Filings — April 03, 2026

Across 38 SEC filings on USA Board Room Changes dated around April 3, 2026, the dominant theme is leadership stability amid 25+ neutral resignations (explicitly not due to disagreements), balanced by 10+ appointments/promotions and retention incentives like equity awards totaling $46M+ (e.g., MercadoLibre LTRP $41.5M, ETHZilla CEO $4.3M). Positive developments in 7 filings highlight management alignment via bonuses (Gibraltar $528K total), option repricings (Skye 2.42M shares), and experienced hires (e.g., Rhythm's Kim Popovits with 40+ years biotech), while negatives are limited to 2 cases: Atlantic's default notices threatening management replacement and HeartSciences COO death. No broad period-over-period deteriorations reported (e.g., 'no performance declines' in 5 filings), with forward-looking reaffirmations (WW guidance intact) signaling continuity; healthcare/biotech shows 8 changes vs tech/finance 12, implying sector-neutral churn. Portfolio-level, 70% neutral sentiment suggests low disruption risk, but high materiality (avg 6/10) in C-suite shifts warrants monitoring for execution gaps. Implications: Bullish for retention-focused firms, cautious on small-caps with disputes.

38 high priority38 total filings

April 02, 2026·daily

US Executive Compensation Proxy SEC Filings — April 02, 2026

Across 50 DEF 14A proxy statements filed April 2, 2026, for 2026 AGMs primarily in mid-May, companies overwhelmingly highlight robust 2025 performance with revenue growth averaging 7-13% YoY where reported (e.g., Equinix +5%, Cohu +13%, Oceaneering +5%), strong shareholder returns via $569M at Empire State Realty, $450M buybacks at Primerica, and dividend increases at Phillips 66 (+10%), UDR (+1.2% for 213th consecutive), and Solstice (first dividend March 2026). Executive compensation is heavily performance-tied (e.g., 95% at-risk for Equinix CEO, 88% Iridium CEO), with governance features like clawbacks, stock ownership (CEO 6x salary at Iridium/First Solar), and independent boards prevalent; sentiments skew positive/neutral (38/50), mixed in 4 cases with declines (Primerica Term Life -10.4% policies, Cohu GAAP loss $(1.59)/share). Portfolio-level trends show margin expansion in select cases (Tenable +140 bps, Waste Connections outsized), capital allocation favoring buybacks/dividends over M&A in most, but outliers like Horizon Space SPAC deadline extension signal risks; implies broad market resilience but watch REITs/financials for relative outperformance amid clustered AGM catalysts May 12-22.

50 high priority50 total filings

April 02, 2026·daily

US Corporate Board Director Changes SEC Filings — April 02, 2026

Across 50 SEC 8-K filings on USA boardroom changes (42 new since last brief), C-suite turnover is elevated with 18 CFO/finance role shifts, 12 CEO/President changes, and 20 director/board adjustments, driven by retirements (10 cases), promotions (8), and experienced external hires (12). Sentiment skews positive/neutral (48/50), with 10 firms reaffirming 2026 guidance post-change (e.g., ESAB, Sally Beauty, Xerox), indicating continuity amid leadership refreshes; one negative (Regenerex CFO suspension) and one mixed (Kiora CDO departure). No broad revenue/margin declines; isolated YoY comp growth (Consumer Portfolio CEO +31%, Pres +44%) and bonus payouts (MAIA $362k total) signal strong FY2025 performance. Biotech (9 filings) and financials (8) lead activity, with net board size reductions in 5 cases. Implications: Positive for growth-oriented firms via M&A-savvy adds (Mama's Creations, Riverview); monitor interims (Oportun) for execution risk. Portfolio trend: Finance roles show +20% hire experience premium vs. average, no insider sales patterns.

50 high priority50 total filings

April 01, 2026·daily

US Executive Compensation Proxy SEC Filings — April 01, 2026

Across 50 DEF 14A proxy statements, US companies showcase resilient 2025 performance with strong capital returns totaling billions (e.g., Las Vegas Sands $2.94B via buybacks/dividends, Weyerhaeuser $766M cash returned), dividend increases (Weyerhaeuser +5% YoY to $0.21/share), and buybacks (Donnelley $172M record), amid performance-tied executive pay hikes (Coeur Mining CEO +51.5% YoY to $6.65M on 133% AIP payout). Period-over-period trends reveal revenue growth (IPG Photonics +3% YoY first since 2021, L3Harris $21.9B), EBITDA records (Sands $5.23B, Weyerhaeuser ~$1.0B), and TSR outperformance (Ventas >35% vs S&P 500 double), though mixed signals include flat segments (Sands Macao EBITDA flat YoY) and LTI shortfalls (Advance Auto 0% payout 3rd year). Forward-looking catalysts cluster in May-June 2026 virtual AGMs for say-on-pay votes and director elections, with growth targets like Weyerhaeuser's $1.5B incremental EBITDA by 2030 and Sands' $8B MBS expansion. No widespread insider selling or pledges noted (e.g., Postal Realty 0% pledged), signaling management alignment; REITs/utilities/defense lead relative performance. Implications: Bullish on real assets (timber/REITs) and backlog-heavy sectors; monitor gaming/mining for regional softness and governance proposals.

50 high priority50 total filings

April 01, 2026·daily

US Executive Officer Management Changes SEC — April 01, 2026

Across 34 filings in the USA Executive & Director Changes stream (22 new since last brief), the dominant theme is aggressive leadership refreshes with 18 new appointments (8 CFOs/COOs, 10+ directors) versus 9 departures/resignations, emphasizing experienced hires in finance, tech/AI, and biopharma to drive 2026 growth amid M&A integrations and strategic pivots. Positive sentiment prevails in 16/34 (47%) filings, driven by hires like Zymeworks' Royalty Pharma CFO and Nexscient's AI CTO acquisition, while neutral/mixed in departures with reaffirmed FY2026 guidance (CVGI, Avantor, Clover). No broad period-over-period financial declines noted, but forward-looking highlights include Bunge's $Viterra synergy PBRSUs (2026-2028), Predictive Oncology's $7.5M 2026 run-rate income est from $12M AI GPU deals, and Associated Banc's post-merger 2025 record net income. Capital allocation trends favor equity incentives (e.g., Consensus Cloud $700K+ grants vesting on 2026 metrics, EPAM $3M RSU retention), signaling alignment without dividends/buybacks mentioned. Portfolio-level pattern: Small/mid-cap turnover (avg materiality 7/10) with interim stability suggests operational continuity, but NovaBay's pharma-to-Stablecoin pivot (materiality 9/10) flags high-risk reinvention. Implications: Bullish for growth-oriented firms, watch CFO interims for execution risks in H1 2026.

34 high priority34 total filings

April 01, 2026·daily

US Corporate Board Director Changes SEC Filings — April 01, 2026

Across 34 filings from April 1, 2026, a surge in C-suite leadership changes dominates, with 9 CFO-related shifts (5 appointments, 3 departures/terminations, 1 interim promotion) signaling high turnover amid growth strategies in tech, biotech, and finance sectors. Board appointments (14 positive/neutral additions) emphasize expertise in finance, M&A, and AI, often tied to post-acquisition integrations (e.g., Bunge Viterra synergies 2026-2028, Associated Banc-Corp merger Q3 2026 conversion). Positive sentiment prevails in 16/34 filings (47%), driven by hires like Royalty Pharma alum at Zymeworks and Goldman Sachs vet at Elauwit, while neutral/mixed in resignations and equity grants. No broad YoY revenue declines noted, but reaffirmations of FY2026 guidance in 5 companies (CVGI, Avantor, Clover Health) despite changes indicate operational stability; equity incentives average $300K-$3M grants vesting 3-4 years on performance metrics. Portfolio trend: 65% of changes post-2025 M&A/IPO, with compensation up 20-50% YoY for new execs (e.g., Consensus CFO base $345K). Implications: Bullish for strategic refreshes in AI/biotech, caution on CFO churn potentially disrupting Q2 2026 reporting.

34 high priority34 total filings

March 31, 2026·daily

US Executive Compensation Proxy SEC Filings — March 31, 2026

Across 50 DEF 14A proxy statements filed around March 31, 2026, companies predominantly highlight strong 2025 performance with disclosed revenue growth averaging +11% YoY (e.g., Range Resources +11%, Wabtec +7.5%, nVent +30%, SPX +14.2%), margin expansions (Ashford +40 bps Hotel EBITDA), and robust capital returns exceeding $10B in aggregate dividends and buybacks (e.g., Marsh & McLennan $3.7B, Akamai $800M repurchases, Range $317M total). Positive sentiment prevails in 14 filings (28%), mixed in 8 (16%), with neutral in the rest; high-materiality (8-9/10) names show portfolio-level trends of deleveraging (e.g., Range net debt -186M, Essential 3.8x leverage), asset sales/strategic shifts (SITE $847.8M sales), and M&A (Transocean/Valaris). Executive compensation is largely performance-tied with above-target payouts (Merit 124.53% of target vs 118.90% 2024), though TSR lags in some (Marsh -11.3% vs S&P). Upcoming May 2026 annual meetings cluster as catalysts for say-on-pay votes (all recommend FOR), board elections, and auditor ratifications, implying low controversy but watch for shareholder proposals. Market implications favor industrials/REITs/utilities with growth+returns; energy/transport outliers signal caution amid headwinds.

50 high priority50 total filings

March 31, 2026·daily

US Executive Officer Management Changes SEC — March 31, 2026

Across 40 filings in the USA Executive & Director Changes stream (March 31, 2026), a dominant theme is leadership consolidation and transitions, with BlackRock appointing Jay Jacobs as President/CEO across 7 iShares ETF sponsors (Bitcoin, Silver, Gold Micro/IAU, Ethereum, Staked Ethereum, Commodity-Indexed Trusts), replacing Shannon Ghia without disputes, signaling centralized expertise amid crypto/commodity volatility. Positive appointments dominate (e.g., experienced execs at Immunic, Skillsoft, AlTi Global, Crown Holdings, Amrize), with 12/40 filings showing bullish sentiment tied to growth strategies, while neutral sentiment prevails in 25/40 and one negative (Rallybio CMO exit). Limited period-over-period data highlights T1 Energy's record Q4 2025 production (1.13 GW, +YoY sales $358.5M) and improved net loss (-$190M vs -$367M Q4 2024), maintaining 2026 guidance (3.1-4.2 GW); other trends include AlTi's $93B AUM and Amrize's $11.8B 2025 revenue. No widespread insider selling/buying noted, but capital allocation via bonuses (High Roller CEO $250K), severance (Eos, Bogota), and RSUs (HF Sinclair Acting CEO ~$105K) indicates retention focus. Portfolio implications: Stability in finance/biotech (e.g., First Foundation merger-ready exec fixes), but monitor successor gaps (Barinthus PAO, MSCI CAO) for operational risks; alpha in pre-catalyst firms like Immunic (Phase 3 data E2026).

40 high priority40 total filings

March 31, 2026·daily

US Corporate Board Director Changes SEC Filings — March 31, 2026

Across 40 filings in the USA Board Room Changes stream (36 new), the dominant theme is executive and board transitions, with 22 appointments/promotions (e.g., experienced directors/CEOs in biotech, banking, wealth mgmt) and 18 resignations/retirements, 70% neutral sentiment, 25% positive, 5% negative/mixed. A cluster of 9 iShares ETF filings reveals BlackRock's uniform leadership shift appointing Jay Jacobs (ex-Global X ETFs, BlackRock equity ETFs head) as Sponsor CEO/President replacing Shannon Ghia across Gold, Bitcoin, Silver, Ethereum, etc., signaling consolidated ETF oversight amid crypto/commodity volatility. Financial trends limited but notable: T1 Energy improved Q4 2025 net loss 48% YoY ($367.2M to $190M), full-year loss narrowed 15% YoY, maintained 2026 production guidance 3.1-4.2 GW with $375-450M EBITDA run-rate 2027. Positive capital allocation in High Roller ($250k CEO bonus), T1 ($160M PTC sale at $0.91/watt), HF Sinclair (RSU grants to acting CEO); no broad insider trading but smooth successions imply management conviction. Portfolio-level: Banking/fintech shows merger-driven stability (First Foundation April 1 close), biotech adds commercialization expertise pre-catalysts (Immunic Phase 3 data E2026), overall bullish for growth sectors via expertise infusion but watch unnamed successors.

40 high priority40 total filings

← All geographies